

CITATION REPORT

List of articles citing

Epidermal growth factor receptor targeting in cancer

DOI: 10.1053/j.seminoncol.2006.04.003
Seminars in Oncology, 2006, 33, 369-85.

Source: <https://exaly.com/paper-pdf/40779743/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
601	Neutron Capture Therapy of Cancer. 2006 , 77-103		1
600	Synthesis of carbon-11 labeled fluorinated 2-arylbenzothiazoles as novel potential PET cancer imaging agents. 2006 , 14, 8599-607		89
599	Epidermal growth factor receptor - mediated signal transduction in the development and therapy of gliomas. 2006 , 12, 7261-70		163
598	Demystifying basal-like breast carcinomas. 2007 , 60, 1328-32		41
597	Cellular dynamics of EGF receptor-targeted synthetic viruses. 2007 , 15, 1297-305		135
596	TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts. 2007 , 104, 12468-73		56
595	Alteration of the serum levels of the epidermal growth factor receptor and its ligands in patients with non-small cell lung cancer and head and neck carcinoma. 2007 , 96, 1569-78		59
594	Thioredoxin and Thioredoxin Reductase As Redox-Sensitive Molecular Targets for Cancer Therapy. 2007 , 13, 3368-3377		59
593	Response to trastuzumab, erlotinib, and bevacizumab, alone and in combination, is correlated with the level of human epidermal growth factor receptor-2 expression in human breast cancer cell lines. 2007 , 6, 2664-74		41
592	Panitumumab: a fully human monoclonal antibody with activity in metastatic colorectal cancer. 2007 , 41, 606-13		15
591	Predicting response to EGFR-tyrosine kinase inhibitors among diverse ancestries: just way too polymorphic. 2007 , 6, 112-5		
590	EGFR signaling is required for TGF-beta 1 mediated COX-2 induction in human bronchial epithelial cells. 2007 , 37, 578-88		27
589	The new paradigm in the treatment of colorectal cancer: are we hitting the right target?. 2007 , 16, 311-24		9
588	Targeting signal transduction in pancreatic cancer treatment. 2007 , 11, 673-94		43
587	Association between functional EGF+61 polymorphism and glioma risk. 2007 , 13, 2621-6		74
586	A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib. 2007 , 67, 6253-62		107
585	Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results. 2007 , 72, 152-9		141

584	High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. 2007 , 25, 3644-8	255
583	Molecular targeting and treatment of an epidermal growth factor receptor-positive glioma using boronated cetuximab. 2007 , 13, 1260-8	101
582	Combined paclitaxel and cetuximab achieved a major response on the skin metastases of a patient with epidermal growth factor receptor-positive, estrogen receptor-negative, progesterone receptor-negative and human epidermal growth factor receptor-2-negative (triple-negative) breast cancer. 2007 , 18, 835-7	26
581	Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). 2007 , 43, 481-9	121
580	HER-3 in colorectal tumorigenesis: from mRNA levels through protein status to clinicopathologic relationships. 2007 , 43, 2602-11	24
579	Rational bases for the development of EGFR inhibitors for cancer treatment. 2007 , 39, 1416-31	95
578	Tissue plasminogen activator induces pancreatic cancer cell proliferation by a non-catalytic mechanism that requires extracellular signal-regulated kinase 1/2 activation through epidermal growth factor receptor and annexin A2. 2007 , 170, 1573-84	63
577	Triple-negative breast cancer: therapeutic options. 2007 , 8, 235-44	664
576	Gestational trophoblastic neoplasia--pathogenesis and potential therapeutic targets. 2007 , 8, 642-50	142
575	Clinical trials update: endocrine and biological therapy combinations in the treatment of breast cancer. 2007 , 9, 112	18
574	Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells. 2007 , 9, R50	40
573	Cetuximab: a review of its use in squamous cell carcinoma of the head and neck and metastatic colorectal cancer. 2007 , 67, 2585-607	76
572	The Rationale for the Combination of Selective EGFR Inhibitors with Cytotoxic Drugs and Radiotherapy. 2007 , 22, 47-52	10
571	Seeing is believing: peptide-based fluorescent sensors of protein tyrosine kinase activity. 2007 , 8, 373-8	65
570	Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk. 2008 , 122, 1530-8	49
569	Serum proteomics of lung adenocarcinomas induced by targeted overexpression of c-raf in alveolar epithelium identifies candidate biomarkers. 2007 , 7, 3980-91	28
568	Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. 2007 , 26, 3291-310	2089
567	From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice. 2007 , 25, 1134-43	165

566	Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?. 2007 , 97, 857-61	39
565	Receptor signaling in cancer. 2007 , 75, 767-9	
564	Protein expression and mutational analysis of epidermal growth factor receptor in renal angiomyolipomas. 2007 , 57, 584-8	1
563	Cytomorphological correlates of epidermal growth factor receptor mutations in lung carcinoma. 2007 , 35, 257-62	13
562	Pancreatic cancer epidermal growth factor receptor (EGFR) intron 1 polymorphism influences postoperative patient survival and in vitro erlotinib response. 2007 , 14, 2150-8	31
561	The role of STATs in lung carcinogenesis: an emerging target for novel therapeutics. 2007 , 85, 427-36	17
560	A phase-I trial of the epidermal growth factor receptor directed bispecific antibody MDX-447 without and with recombinant human granulocyte-colony stimulating factor in patients with advanced solid tumors. 2008 , 57, 155-63	68
559	Mechanisms of resistance to EGFR inhibitors. 2007 , 2, 31-37	5
558	Molecular targeted therapy for advanced hepatocellular carcinoma. 2007 , 2, 199-210	6
557	Targeted therapies and surgical issues in gastrointestinal cancers. 2008 , 3, 119-125	6
556	The role of biologics in stomach cancer. 2008 , 3, 71-79	2
555	Block copolymer micelles conjugated with anti-EGFR antibody for targeted delivery of anticancer drug. 2008 , 46, 7321-7331	51
554	Final survival and safety results from a multicenter, open-label, phase 3b trial of erlotinib in patients with advanced nonsmall cell lung cancer. 2008 , 112, 2749-55	21
553	Targeted therapy in head and neck cancer: state of the art 2007 and review of clinical applications. 2008 , 112, 2635-45	45
552	Pan-HER biologics (Hermodulins) for the treatment of cancer. 2008 , 69, 472-479	
551	Usefulness of monitoring the circulating Krebs von den Lungen-6 levels to predict the clinical outcome of patients with advanced nonsmall cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. 2008 , 122, 2612-20	39
550	Epidermal growth factor receptor regulates osteoclast differentiation and survival through cross-talking with RANK signaling. 2008 , 217, 409-22	70
549	Effector mechanisms of therapeutic antibodies against ErbB receptors. 2008 , 20, 436-43	38

548	The ERBB3 receptor in cancer and cancer gene therapy. 2008 , 15, 413-48	174
547	Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. 2008 , 27, 3944-56	448
546	EGFR-targeting drugs in combination with cytotoxic agents: from bench to bedside, a contrasted reality. 2008 , 99, 1-5	44
545	Enzastaurin inhibits tumours sensitive and resistant to anti-EGFR drugs. 2008 , 99, 473-80	18
544	Absence of epidermal growth factor receptor mutations in cervical cancer. 2008 , 18, 749-54	30
543	Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization. 2008 , 13, 365-73	126
542	Clinical approaches to minimize rash associated with EGFR inhibitors. 2008 , 35, 103-11	17
541	Structure-based view of epidermal growth factor receptor regulation. 2008 , 37, 353-73	236
540	Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer. 2008 , 26, 1427-34	113
539	EGFR Signaling Networks in Cancer Therapy. 2008 ,	7
538	Targeted Radionuclide Tumor Therapy. 2008 ,	9
537	Monoclonal antibody therapy for prostate cancer. 2008 , 237-56	10
536	EGFR and ErbB2 are functionally coupled to CD44 and regulate shedding, internalization and motogenic effect of CD44. 2008 , 263, 231-42	33
535	The efficacy and toxicity of EGFR in the settings of radiotherapy: Focus on published clinical trials. 2008 , 44, 2133-43	18
534	Epidermal growth factor (EGF) receptor targeted delivery of PEGylated adenovirus. 2008 , 366, 769-74	38
533	Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. 2008 , 9, 962-72	623
532	Basal-like breast cancer: a critical review. 2008 , 26, 2568-81	657
531	Diagnostic and prognostic sarcoma signatures. 2008 , 12, 359-74	20

530	Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. 2008 , 26, 1626-34	2666
529	EGFR inhibition as a therapy for head and neck squamous cell carcinoma. 2008 , 17, 1517-31	39
528	Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications. 2008 , 5, 521-30	94
527	Thymidine kinase 1 as a molecular target for boron neutron capture therapy of brain tumors. 2008 , 105, 17493-7	55
526	Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK. 2008 , 19, 1288-1292	95
525	Novel agents in the era of targeted therapy: what have we learned and how has our practice changed?. 2008 , 19 Suppl 7, vii281-8	3
524	Human epidermal growth factor receptor (HER-1:HER-3) Fc-mediated heterodimer has broad antiproliferative activity in vitro and in human tumor xenografts. 2008 , 7, 3223-36	24
523	Killing cancer cells by targeting the EGF receptor. 2008 , 7, 243-4	0
522	Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs. 2008 , 98, 923-30	118
521	Tumor cell killing mechanisms of epidermal growth factor receptor (EGFR) antibodies are not affected by lung cancer-associated EGFR kinase mutations. 2008 , 180, 4338-45	20
520	Determinants of RASistance to anti-epidermal growth factor receptor agents. 2008 , 26, 1582-4	69
519	Molecular targeting and treatment of composite EGFR and EGFRvIII-positive gliomas using boronated monoclonal antibodies. 2008 , 14, 883-91	85
518	Requirement of hypoxia-inducible factor-1alpha down-regulation in mediating the antitumor activity of the anti-epidermal growth factor receptor monoclonal antibody cetuximab. 2008 , 7, 1207-17	58
517	Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells. 2008 , 14, 5069-80	127
516	The potential for cancer combination therapy with multi-targeted, single-protein pharmaceuticals. 2008 , 3, 147-52	1
515	Impact of basal-like breast carcinoma determination for a more specific therapy. 2008 , 75, 95-103	25
514	The potential role of mTOR inhibitors in non-small cell lung cancer. 2008 , 13, 139-47	98
513	Validation of gefitinib effectiveness in a broad panel of head and neck squamous carcinoma cells. 2008 , 21, 809-17	2

512	Triple negative breast cancer: current understanding of biology and treatment options. 2008 , 20, 40-6	50
511	Lysophosphatidic acid induces rapid and sustained decreases in epidermal growth factor receptor binding via different signaling pathways in BEAS-2B airway epithelial cells. 2008 , 325, 809-17	10
510	Association of EGFR c.2073A>T Polymorphism with Decreased Risk of Diffusely Infiltrating Astrocytoma in a Brazilian Case-Control Study. 2008 , 23, 140-146	4
509	Small molecule tyrosine kinase inhibitors in pancreatic cancer. 2008 , 2, 707-15	13
508	The role of inhibitors of the epidermal growth factor in management of head and neck cancer. 2008 , 6, 696-706	11
507	Rational optimization of a bispecific ligand trap targeting EGF receptor family ligands. 2009 , 15, 11-20	7
506	[KRAS status versus EGFR status in lung cancer therapy]. 2009 , 96 Suppl, S75-83	1
505	Update in antiepidermal growth factor receptor therapy in the management of metastatic colorectal cancer. 2009 , 2009, 967920	6
504	Management of EGFR-Mutant Non-Small Cell Lung Cancer: Focus on Gefitinib. 2009 , 1, CMT.S2122	
503	Antibodies specifically targeting a locally misfolded region of tumor associated EGFR. 2009 , 106, 5082-7	55
502	A review on the treatment of relapsed/metastatic head and neck cancer. 2009 , 10, 2625-32	5
501	A perspective on challenges and issues in biomarker development and drug and biomarker codevelopment. 2009 , 101, 1453-63	88
500	Developing dendritic cell-based therapies to condition immune responses to novel oncogenic proteins and stem cells. 2009 , 2, 517-26	
499	Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation. 2009 , 69, 5851-9	144
498	EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer. 2009 , 62, 970-7	94
497	Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response. 2009 ,	2
496	Antitumor effect in medulloblastoma cells by gefitinib: Ectopic HER2 overexpression enhances gefitinib effects in vivo. 2009 , 11, 250-9	21
495	Development of extracellular signal-regulated kinase inhibitors. 2009 , 9, 678-89	26

494	Chemokine-chemokine receptors in cancer immunotherapy. 2009 , 1, 109-27	21
493	A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies. 2009 , 15, 6702-8	74
492	EGF-receptor regulation of matrix metalloproteinases in epithelial ovarian carcinoma. 2009 , 5, 323-38	27
491	Identification of novel small-molecule compounds that inhibit the proproliferative Kruppel-like factor 5 in colorectal cancer cells by high-throughput screening. 2009 , 8, 563-70	28
490	Dose-dependent increases in circulating TGF-alpha and other EGFR ligands act as pharmacodynamic markers for optimal biological dosing of cetuximab and are tumor independent. 2009 , 15, 2397-405	37
489	Human-like mouse models for testing the efficacy and safety of anti-beta2-microglobulin monoclonal antibodies to treat myeloma. 2009 , 15, 951-9	14
488	Molecular target approaches in head and neck cancer: epidermal growth factor receptor and beyond. 2009 , 19, 63-8	52
487	The crosstalk between EGF, IGF, and Insulin cell signaling pathways--computational and experimental analysis. 2009 , 3, 88	41
486	Novel agents on the horizon for cancer therapy. 2009 , 59, 111-37	241
485	Extending outcomes: epidermal growth factor receptor-targeted monoclonal antibodies in non-small-cell lung cancer. 2009 , 10 Suppl 1, S24-9	4
484	ErbBs in lung cancer. 2009 , 315, 557-71	57
483	Interaction of antibodies with ErbB receptor extracellular regions. 2009 , 315, 659-70	71
482	EGF receptor inhibitors in the treatment of glioblastoma multiform: old clinical allies and newly emerging therapeutic concepts. 2009 , 625, 23-30	24
481	Sequence dependence of cell growth inhibition by EGFR-tyrosine kinase inhibitor ZD1839, docetaxel, and cisplatin in head and neck cancer. 2009 , 31, 1263-73	3
480	Targeted radionuclide therapy in head and neck cancer. 2010 , 32, 666-78	10
479	Epidermal growth factor receptor gene mutations in papillary thyroid carcinoma. 2009 , 124, 2744-9	39
478	A novel mechanism for anti-EGFR antibody action involves chemokine-mediated leukocyte infiltration. 2009 , 124, 2589-96	42
477	Combined therapies for cancer: a review of EGFR-targeted monotherapy and combination treatment with other drugs. 2009 , 135, 1137-48	34

476	Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer. 2009 , 28, 335-44	272
475	Epidermal growth factor receptor pathway as therapeutic development in head and neck cancers: present and future. 2009 , 3, 137-148	1
474	Immunotherapy of head and neck cancer using tumor antigen-specific monoclonal antibodies. 2009 , 11, 156-62	17
473	Therapeutic efficacy of ¹⁷⁷ Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy. 2009 , 69, 92-104	43
472	Epidermal growth factor receptor lacking C-terminal autophosphorylation sites retains signal transduction and high sensitivity to epidermal growth factor receptor tyrosine kinase inhibitor. 2009 , 100, 552-7	13
471	ZIP: a novel transcription repressor, represses EGFR oncogene and suppresses breast carcinogenesis. 2009 , 28, 2763-76	46
470	Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. 2009 , 28, 3009-21	233
469	EGFR mutation testing in NSCLC: Patterns of care and outcomes in Western Australia. 2009 , 5, 66-71	3
468	Preclinical evaluation of a monoclonal antibody targeting the epidermal growth factor receptor as a radioimmunodiagnostic and radioimmunotherapeutic agent. 2009 , 157, 1541-8	26
467	Boron neutron capture therapy of EGFR or EGFRvIII positive gliomas using either boronated monoclonal antibodies or epidermal growth factor as molecular targeting agents. 2009 , 67, S328-31	45
466	Delivery of sodium borocaptate to glioma cells using immunoliposome conjugated with anti-EGFR antibodies by ZZ-His. 2009 , 30, 1746-55	80
465	Epidermal growth factor receptor inhibitors: current status and future directions. 2009 , 33, 245-94	9
464	EGFR protein overexpression and gene copy number increases in oral tongue squamous cell carcinoma. 2009 , 45, 1700-8	44
463	The predictive value of epidermal growth factor receptor tests in patients with pulmonary adenocarcinoma: review of current "best evidence" with meta-analysis. 2009 , 40, 356-65	34
462	Encyclopedia of Cancer. 2008 , 981-981	
461	KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. 2009 , 27, 5931-7	459
460	Targeting EGFR with photodynamic therapy in combination with Erbitux enhances in vivo bladder tumor response. 2009 , 8, 94	41
459	Triple-negative/basal-like breast cancer: review. 2009 , 41, 40-7	204

458	A truncated soluble epidermal growth factor receptor-Fc fusion ligand trap displays anti-tumour activity in vivo. 2009 , 27, 141-54	18
457	Triple negative breast cancers: clinical and prognostic implications. 2009 , 45 Suppl 1, 27-40	173
456	Targeting of epidermal growth factor receptor (EGFR)-expressing tumor cells with sterically stabilized affibody liposomes (SAL). 2009 , 20, 1201-8	46
455	EGFR signaling and drug discovery. 2009 , 77, 400-10	324
454	Sensitive detection of KRAS mutations in archived formalin-fixed paraffin-embedded tissue using mutant-enriched PCR and reverse-hybridization. 2009 , 11, 508-13	32
453	Inhibition of functional HER family members increases the sensitivity to docetaxel in human ovarian cancer cell lines. 2009 , 20, 450-60	24
452	Therapeutic Antibodies from XenoMouse Transgenic Mice. 89-99	
451	Clinical development of inhibitors of the insulin-like growth factor receptor in oncology. 2009 , 10, 923-36	52
450	Dual EGFR and COX-2 inhibition as a novel approach to targeting head and neck squamous cell carcinoma. 2009 , 9, 931-7	28
449	Integration of anti-epidermal growth factor receptor therapies with cytotoxic chemotherapy. 2010 , 16, 226-34	5
448	The natural tumor suppressor protein maspin and potential application in non small cell lung cancer. 2010 , 16, 1877-81	24
447	EGFR, HER2 and HER3 expression in primary colorectal carcinomas and corresponding metastases: Implications for targeted radionuclide therapy. 2010 , 25,	0
446	Anti-EGFR-miniantibody-barnase immunoconjugate is highly toxic for human tumor cells. 2010 , 434, 270-3	
445	Epidermal growth factor receptor inhibitors for radiotherapy: biological rationale and preclinical results. 2008 , 60, 1019-28	25
444	Cancer, chitosan nanoparticles and catalytic nucleic acids. 2010 , 61, 3-12	49
443	p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging. 2010 , 37, 250-9	161
442	PET imaging of HER1-expressing xenografts in mice with ⁸⁶ Y-CHX-A''-DTPA-cetuximab. 2010 , 37, 1368-76	61
441	Pharmacogenetic testing and therapeutic drug monitoring are complementary tools for optimal individualization of drug therapy. 2010 , 66, 755-74	48

440	Myoepithelial carcinoma of the breast: a clinicopathological and immunohistochemical study of 15 diagnostically challenging cases. 2010 , 457, 337-45	23
439	Le panitumumab (Vectibix®) en oncologie digestive: quel rationnel pharmacologique et pharmacocinétique ?. 2010 , 12, 565-571	
438	In silico identification of significant detrimental missense mutations of EGFR and their effect with 4-anilinoquinazoline-based drugs. 2010 , 160, 1723-33	12
437	PDEF and PDEF-induced proteins as candidate tumor antigens for T cell and antibody-mediated immunotherapy of breast cancer. 2010 , 46, 206-15	4
436	Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas. 2010 , 10, 189	58
435	The epidermal growth factor receptor modulates DNA double-strand break repair by regulating non-homologous end-joining. 2010 , 9, 889-97	106
434	A novel anti-EGFR monoclonal antibody inhibiting tumor cell growth by recognizing different epitopes from cetuximab. 2010 , 145, 84-91	16
433	Peptide mimotopes recognized by antibodies cetuximab and matuzumab induce a functionally equivalent anti-EGFR immune response. 2010 , 29, 4517-27	28
432	Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients. 2010 , 102, 1137-44	21
431	Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. 2010 , 10, 760-74	802
430	Integrating molecular diagnostics into anticancer drug discovery. 2010 , 9, 523-35	45
429	Development of an ErbB-overexpressing A-431 optical reporting tumor xenograft model to assess targeted photodynamic therapy regimens. 2010 , 86, 1379-89	2
428	Cell line and drug-dependent effect of ERBB3 on cancer cell proliferation, chemosensitivity, and multidrug actions. 2010 , 49	0
427	Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using Zr-DFO-trastuzumab. 2010 , 5, e8859	112
426	Targeting the EGF receptor for ovarian cancer therapy. 2010 , 2010, 414676	52
425	Preparation, biological evaluation, and pharmacokinetics of the human anti-HER1 monoclonal antibody panitumumab labeled with 86Y for quantitative PET of carcinoma. 2010 , 51, 942-50	51
424	Effects of the EGFR Inhibitor Erlotinib on Magnesium Handling. 2010 , 21, 1309-16	44
423	Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy. 2010 , 70, 588-97	192

422	Differential mechanisms of acquired resistance to insulin-like growth factor-i receptor antibody therapy or to a small-molecule inhibitor, BMS-754807, in a human rhabdomyosarcoma model. 2010 , 70, 7221-31	93
421	Activity of cetuximab as single agent in a patient with relapsed multiple myeloma. 2010 , 51, 562-4	4
420	Systems Biology in Drug Discovery: Using Predictive Biomedicine to Guide Development Choices for Novel Agents in Cancer. 2010 , 399-414	1
419	Colorectal cancer in review: the role of the EGFR pathway. 2010 , 19, 357-69	42
418	sZIP, an alternative splice variant of ZIP, antagonizes transcription repression and growth inhibition by ZIP. 2010 , 285, 14301-7	9
417	From combinatorial peptide selection to drug prototype (II): targeting the epidermal growth factor receptor pathway. 2010 , 107, 5118-23	40
416	HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancer. 2010 , 8, e1000563	101
415	Challenges of drug resistance in the management of pancreatic cancer. 2010 , 10, 1647-61	38
414	Passive antibody-mediated immunotherapy for the treatment of malignant gliomas. 2010 , 21, 67-76	11
413	Molecular aspects of thyroid hormone actions. 2010 , 31, 139-70	904
412	Safety and efficacy of panitumumab therapy after progression with cetuximab: experience at two institutions. 2010 , 9, 315-8	36
411	Helicobacter pylori CagL activates ADAM17 to induce repression of the gastric H, K-ATPase alpha subunit. 2010 , 139, 239-48	85
410	Targeted immunotherapy for colorectal cancer: monoclonal antibodies and immunotoxins. 2010 , 19 Suppl 1, S67-77	14
409	Pharmacogenetics: Making cancer treatment safer and more effective. 2010 ,	1
408	Cardiac side-effects of cancer chemotherapy. 2010 , 144, 3-15	284
407	Fusion protein based on Grb2-SH2 domain for cancer therapy. 2010 , 399, 262-7	6
406	E3 ubiquitin ligases in ErbB receptor quantity control. 2010 , 21, 936-43	34
405	Réhabilitation secondaire des métastases hépatiques initialement non réhabiles chez les patients porteurs d'un cancer colorectal : un véritable enjeu !. 2010 , 147, S40-S54	

404	What can the molecular pathologist offer for optimal decision making?. 2010 , 21 Suppl 7, vii123-9	3
403	Ovarian Cancer. 2010 ,	1
402	EGFR upregulates inflammatory and proliferative responses in human lung adenocarcinoma cell line (A549), induced by lower dose of cadmium chloride. 2011 , 23, 339-48	30
401	Cetuximab in the treatment of patients with colorectal cancer. 2011 , 11, 937-49	38
400	Receptor heterodimerization: a new mechanism for platelet-derived growth factor induced resistance to anti-epidermal growth factor receptor therapy for bladder cancer. 2011 , 185, 693-700	22
399	Encyclopedia of Cancer. 2011 , 1244-1244	
398	Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors. 2011 , 73, 195-202	78
397	Targeted therapies for gastric cancer: current status. 2011 , 71, 1367-84	31
396	Encyclopedia of Cancer. 2011 , 1209-1209	
395	Epidermal growth factor receptor-targeted (131)I-therapy of liver cancer following systemic delivery of the sodium iodide symporter gene. 2011 , 19, 676-85	85
394	The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancer. 2011 , 11, 673-82	34
393	Diverse effects of combined radiotherapy and EGFR inhibition with antibodies or TK inhibitors on local tumour control and correlation with EGFR gene expression. 2011 , 99, 323-30	66
392	Dual targeting of EGFR and focal adhesion kinase in 3D grown HNSCC cell cultures. 2011 , 99, 279-86	36
391	Development of a multicomponent prediction model for acute esophagitis in lung cancer patients receiving chemoradiotherapy. 2011 , 81, 537-44	21
390	Encyclopedia of Cancer. 2011 , 1244-1248	2
389	Clinical application of molecular pathology in sarcomas. 2011 , 23, 379-84	15
388	Nimotuzumab and cetuximab block ligand-independent EGF receptor signaling efficiently at different concentrations. 2011 , 34, 550-5	29
387	Emerging therapies in the treatment of locally advanced squamous cell cancers of head and neck. 2011 , 6, 246-57	7

386	Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors. 2011 , 50, 129-46	45
385	Gene status of head and neck squamous cell carcinoma cell lines and cetuximab-mediated biological activities. 2011 , 102, 1717-23	12
384	Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer. 2011 , 104, 488-95	84
383	Structure of the Fab fragment of the anti-murine EGFR antibody 7A7 and exploration of its receptor binding site. 2011 , 48, 1578-85	5
382	Comparative analysis of binding affinities to epidermal growth factor receptor of monoclonal antibodies nimotuzumab and cetuximab using different experimental animal models. 2011 , 32, 531-4	12
381	Small tyrosine kinase inhibitors interrupt EGFR signaling by interacting with erbB3 and erbB4 in glioblastoma cell lines. 2011 , 317, 1476-89	42
380	Plasma and pleural fluid pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small-cell lung cancer with pleural effusion. 2011 , 12, 307-12	18
379	Metastatic triple-negative breast cancer. 2011 , 23, 587-600	81
378	Augmented stress-responsive characteristics of cell lines in narrow confinements. 2011 , 3, 684-95	20
377	Differential and synergistic effects of epidermal growth factor receptor antibodies on unliganded ErbB dimers and oligomers. 2011 , 50, 3581-90	13
376	KRAS, BRAF, EGFR and HER2 gene status in a Spanish population of colorectal cancer. 2011 , 38, 1315-20	27
375	PIK3CA mutations in KRAS and BRAF wild type colorectal cancer patients. A study of Spanish population. 2011 , 38, 1347-51	12
374	A phase I study evaluating the role of the anti-epidermal growth factor receptor (EGFR) antibody cetuximab as a radiosensitizer with chemoradiation for locally advanced pancreatic cancer. 2011 , 67, 891-7	28
373	Argonaute2 is a potential target for siRNA-based cancer therapy for HT1080 human fibrosarcoma. 2011 , 1, 277-88	2
372	A first synthesis of 18F-radiolabeled lapatinib: a potential tracer for positron emission tomographic imaging of ErbB1/ErbB2 tyrosine kinase activity. 2011 , 54, 633-636	15
371	Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor. 2011 , 3, 584-95	77
370	Changing pathology with changing drugs: tumors of the gastrointestinal tract. 2011 , 78, 76-89	13
369	Targeted therapy in nonmelanoma skin cancers. 2011 , 3, 2255-73	16

368	Preclinical pharmacokinetics and safety of Sym004: a synergistic antibody mixture directed against epidermal growth factor receptor. 2011 , 17, 5962-72	34
367	Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells. 2011 , 105, 1554-62	54
366	EGFR-PI3K-AKT-mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy. 2011 , 15, 63-74	116
365	Basal phenotype breast cancer: implications for treatment and prognosis. 2011 , 7, 181-202	19
364	Pharmacodynamic modeling of anti-cancer activity of tetraiodothyroacetic acid in a perfused cell culture system. 2011 , 7, e1001073	42
363	Epidermal growth factor receptor in pancreatic cancer. 2011 , 3, 1513-26	77
362	EGFR-Targeting as a Biological Therapy: Understanding Nimotuzumab's Clinical Effects. 2011 , 3, 2014-31	23
361	The effect of cytotoxic chemotherapy on the risk of high-grade acneiform rash to cetuximab in cancer patients: a meta-analysis. 2011 , 22, 2366-2374	17
360	Phage displayed peptides/antibodies recognizing growth factors and their tyrosine kinase receptors as tools for anti-cancer therapeutics. 2012 , 13, 5254-77	6
359	Hepatitis C virus induces epidermal growth factor receptor activation via CD81 binding for viral internalization and entry. 2012 , 86, 10935-49	99
358	R(h)oads to microvesicles. 2012 , 3, 219-24	51
357	What can molecular pathology offer for optimal decision making?. 2012 , 23 Suppl 10, x63-70	2
356	Focal adhesion-chromatin linkage controls tumor cell resistance to radio- and chemotherapy. 2012 , 2012, 319287	18
355	Immunohistochemical correlation of epidermal growth factor receptor and c-erbB-2 with histopathologic grading of mucoepidermoid carcinoma. 2012 , 8, 586-90	9
354	Research progress on criteria for discontinuation of EGFR inhibitor therapy. 2012 , 5, 263-70	5
353	Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors. 2012 , 23, 463-71	18
352	TRPC1 protein channel is major regulator of epidermal growth factor receptor signaling. 2012 , 287, 16146-57	67
351	EGFR and KRAS mutational analysis and their correlation to survival in pancreatic and periampullary cancer. 2012 , 41, 428-34	43

350	Mechanisms of acquired resistance to anti-EGF receptor treatment in colorectal cancer. 2012 , 1, 491-502	1
349	Nonthermal Plasma-Mediated Cancer Cell Death; Targeted Cancer Treatment. 2012 , 7, 399-404	12
348	Nuclear epidermal growth factor receptor and p16 expression in head and neck squamous cell carcinoma. 2012 , 122, 2762-8	16
347	Therapeutic application of monoclonal antibodies in cancer: advances and challenges. 2012 , 104, 41-59	52
346	Preparation and preclinical evaluation of ¹⁷⁷ Lu-nimotuzumab targeting epidermal growth factor receptor overexpressing tumors. 2012 , 39, 3-13	30
345	An ErbB-3 antibody, MP-RM-1, inhibits tumor growth by blocking ligand-dependent and independent activation of ErbB-3/Akt signaling. 2012 , 31, 1275-86	26
344	Epidermal growth factor receptor-targeted photosensitizer selectively inhibits EGFR signaling and induces targeted phototoxicity in ovarian cancer cells. 2012 , 321, 120-7	55
343	Emerging therapies for urothelial cancer. 2012 , 38, 311-7	6
342	Probing the kinome in real time with fluorescent peptides. 2012 , 41, 1652-64	72
341	Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer. 2012 , 84, 1388-99	62
340	Marsdenia tenacissima extract restored gefitinib sensitivity in resistant non-small cell lung cancer cells. 2012 , 75, 30-7	53
339	Biomedical Applications of Gold Nanoparticles. 2012 , 101-145	3
338	Biological drugs: classic adverse effects and new clinical evidences. 2012 , 12, 285-97	6
337	Targeting angiogenesis in gynecologic cancers. 2012 , 26, 543-63, viii	13
336	Combining chemotherapy with epidermal growth factor receptor inhibition in advanced non-small cell lung cancer. 2012 , 4, 173-81	14
335	Irreversible inhibition of epidermal growth factor receptor activity by 3-aminopropanamides. 2012 , 55, 2251-64	48
334	Effect of radiotherapy on expression of hyaluronan and EGFR and presence of mast cells in squamous cell carcinoma of the head and neck. 2012 , 4, 1177-1182	6
333	Role of anti-EGFR target therapy in colorectal carcinoma. 2012 , 4, 12-22	1

332	Role of anti-EGFR target therapy in colorectal carcinoma. 2012 , E4, 12-22	5
331	Integrin-Mediated Actions of Thyroid Hormone Analogues on Tumor Cell Chemosensitivity, Integrin-Growth Factor Receptor Crosstalk and Inflammatory Gene Expression. 2012 , 1,	2
330	The role of CXC chemokines and their receptors in the progression and treatment of tumors. 2012 , 43, 699-713	39
329	Celecoxib inactivates epithelial-mesenchymal transition stimulated by hypoxia and/or epidermal growth factor in colon cancer cells. 2012 , 51, 783-95	24
328	Increased expression of the integral membrane proteins EGFR and FGFR3 in anti-apoptotic Chinese hamster ovary cell lines. 2012 , 59, 155-62	7
327	Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer. 2012 , 30, 1138-43	54
326	In-depth biophysical analysis of interactions between therapeutic antibodies and the extracellular domain of the epidermal growth factor receptor. 2012 , 421, 138-51	12
325	Sialylation of epidermal growth factor receptor regulates receptor activity and chemosensitivity to gefitinib in colon cancer cells. 2012 , 83, 849-57	96
324	Computational model of EGFR and IGF1R pathways in lung cancer: a Systems Biology approach for Translational Oncology. 2012 , 30, 142-53	25
323	Clinical Implications and Quality Assurance of Molecular Testing for EGFR-Targeting Agents in Colorectal Cancer. 2012 , 8, 42-50	4
322	Antibody-functionalized nanoparticles for imaging cancer: influence of conjugation to gold nanoparticles on the biodistribution of 89Zr-labeled cetuximab in mice. 2013 , 8, 402-8	76
321	Molecular Mechanisms of Tumor Cell Resistance to Chemotherapy. 2013 ,	5
320	Nitric oxide donating anilopyrimidines: synthesis and biological evaluation as EGFR inhibitors. 2013 , 66, 82-90	14
319	Four-membered heterocycles-containing 4-anilino-quinazoline derivatives as epidermal growth factor receptor (EGFR) kinase inhibitors. 2013 , 23, 5385-8	19
318	Resistance to Immunotherapeutic Antibodies in Cancer. 2013 ,	1
317	Monoclonal antibodies: potential new therapeutic treatment against multiple myeloma. 2013 , 90, 441-68	34
316	Robustness of complex feedback systems: application to oncological biochemical networks. 2013 , 86, 1304-1321	4
315	The development of a Functional Assessment of Cancer Therapy (FACT) questionnaire to assess dermatologic symptoms associated with epidermal growth factor receptor inhibitors (FACT-EGFRI-18). 2013 , 21, 1033-41	31

314	Targeting the ERBB family in cancer: couples therapy. 2013 , 13, 663-73	275
313	A patient-derived somatic mutation in the epidermal growth factor receptor ligand-binding domain confers increased sensitivity to cetuximab in head and neck cancer. 2013 , 49, 2345-55	10
312	Effect of blockade of the EGF system on wound healing in patients vaccinated with CIMAvax [®] EGF. 2013 , 11, 275	11
311	NOX4 mediates cytoprotective autophagy induced by the EGFR inhibitor erlotinib in head and neck cancer cells. 2013 , 272, 736-45	46
310	Pharmacogenetic predictors for EGFR-inhibitor-associated skin toxicity. 2013 , 13, 181-8	26
309	Clinical significance of KRAS gene mutation and epidermal growth factor receptor expression in Japanese patients with squamous cell carcinoma of the larynx, oropharynx and hypopharynx. 2013 , 18, 454-63	15
308	Oligopeptides derived from autophosphorylation sites of EGF receptor suppress EGF-stimulated responses in human lung carcinoma A549 cells. 2013 , 698, 87-94	5
307	Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation. 2013 , 73, 824-33	147
306	Lack of expression of the proteins GMPR2 and PPAR α are associated with the basal phenotype and patient outcome in breast cancer. 2013 , 137, 127-37	15
305	A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer. 2013 , 49, 3763-72	112
304	EGFR inhibition in non-small cell lung cancer: current evidence and future directions. 2013 , 1, 2	25
303	Controversies in anti-epidermal growth factor receptor therapy in metastatic colorectal cancer. 2013 , 119, 1941-50	14
302	A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction. 2013 , 62, 540-9	107
301	IL-1 and EGF regulate expression of genes important in inflammation and cancer. 2013 , 62, 22-33	48
300	Genomic dysregulation in gastric tumors. 2013 , 107, 237-42	21
299	Cetuximab: still an option in the treatment of pancreatic cancer?. 2013 , 13, 791-801	14
298	Novel hybrids of (phenylsulfonyl)furoxan and anilino-pyrimidine as potent and selective epidermal growth factor receptor inhibitors for intervention of non-small-cell lung cancer. 2013 , 56, 4738-48	52
297	Structural modifications of (Z)-3-(2-aminoethyl)-5-(4-ethoxybenzylidene)thiazolidine-2,4-dione that improve selectivity for inhibiting the proliferation of melanoma cells containing active ERK signaling. 2013 , 11, 3706-32	26

296	Proteomic analysis of temporally stimulated ovarian cancer cells for biomarker discovery. 2013 , 12, 356-68	17
295	UBE4B levels are correlated with clinical outcomes in neuroblastoma patients and with altered neuroblastoma cell proliferation and sensitivity to epidermal growth factor receptor inhibitors. 2013 , 119, 915-23	27
294	Bridging oncology and immunology: expanding horizons with innovative peptide vaccines and peptidomimetics. 2013 , 5, 1159-63	9
293	Synthesis, bioanalysis and biodistribution of photosensitizer conjugates for photodynamic therapy. 2013 , 5, 1099-114	29
292	A real-life experience using panitumumab in chemo-refractory metastatic colorectal cancer patients: a retrospective analysis at the Jewish General Hospital, 2009-2012. 2013 , 20, e107-12	2
291	Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer. 2013 , 3, 29-35	1
290	Cetuximab hypersensitivity infusion reactions: Incidence and risk factors. 2013 , 19, 222-7	17
289	Antiproliferative effect of a novel mTOR inhibitor temsirolimus contributes to the prolonged survival of orthotopic esophageal cancer-bearing mice. 2013 , 14, 230-6	24
288	Sym004, a novel anti-EGFR antibody mixture, augments radiation response in human lung and head and neck cancers. 2013 , 12, 2772-81	11
287	Imaging of epidermal growth factor receptor expression in head and neck cancer with SPECT/CT and ¹¹¹ In-labeled cetuximab-F(ab') ₂ . 2013 , 54, 2118-24	36
286	Pruritus to anticancer agents targeting the EGFR, BRAF, and CTLA-4. 2013 , 26, 135-48	37
285	Preclinical evaluation of radiolabelled nimotuzumab, a promising monoclonal antibody targeting the epidermal growth factor receptor. 2013 , 56, 280-8	6
284	Mechanisms of resistance to EGFR targeted therapies. 2013 , 14, 304-14	41
283	Not all antibodies are equal. 2013 , 14, 1075-6	
282	Combining molecular targeted agents with radiation therapy for malignant gliomas. 2013 , 6, 1079-95	15
281	Targeting the calmodulin-regulated ErbB/Grb7 signaling axis in cancer therapy. 2013 , 16, 177-89	14
280	Safety and efficacy of panitumumab therapy after metastatic colorectal cancer progression with cetuximab: Experience at a single Japanese institution. 2013 , 5, 1331-1334	9
279	Epidermal Growth Factor Receptor Protein: A Biological Marker for Oral Precancer and Cancer. 2014 , 2014, 1-7	7

278	Nanotetrac targets integrin $\alpha 3$ on tumor cells to disorder cell defense pathways and block angiogenesis. 2014 , 7, 1619-24	36
277	EGFR and c-Met Inhibitors are Effective in Reducing Tumorigenicity in Cancer. 2014 , 05,	5
276	Nimotuzumab in combination with radiotherapy in high grade glioma patients: a single institution experience. 2014 , 15, 504-9	28
275	Serum levels of hepatocyte growth factor and epiregulin are associated with the prognosis on anti-EGFR antibody treatment in KRAS wild-type metastatic colorectal cancer. 2014 , 110, 2716-27	48
274	Role of receptor tyrosine kinases and their ligands in glioblastoma. 2014 , 3, 199-235	54
273	Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS. 2014 , 4, 204	111
272	A panel of biomarkers for predicting response to postoperative RT for laryngeal cancer?. 2014 , 35, 771-8	4
271	Emerging combination therapies to overcome resistance in EGFR-driven tumors. 2014 , 25, 127-39	14
270	Phase II trial of cetuximab plus cisplatin and irinotecan in patients with cisplatin and irinotecan-refractory metastatic esophagogastric cancer. 2014 , 37, 126-30	6
269	Exploring inhibitory potential of Curcumin against various cancer targets by in silico virtual screening. 2014 , 6, 13-24	16
268	Efficacy of nimotuzumab plus gemcitabine usage as first-line treatment in patients with advanced pancreatic cancer. 2014 , 35, 2313-8	24
267	Optimization of Anti-EGFR Treatment of Advanced Colorectal Cancer. 2014 , 10, 263-271	1
266	Viruses exploit the function of epidermal growth factor receptor. 2014 , 24, 274-86	51
265	Comparison of KRAS mutation analysis of colorectal cancer samples by standard testing and next-generation sequencing. 2014 , 67, 764-7	23
264	Determination of receptor protein binding site specificity and relative binding strength using a time-resolved competition assay. 2014 , 70, 145-51	2
263	Design and synthesis of Lapatinib derivatives containing a branched side chain as HER1/HER2 targeting antitumor drug candidates. 2014 , 87, 631-42	17
262	Epidermal growth factor receptor signalling in keratinocyte biology: implications for skin toxicity of tyrosine kinase inhibitors. 2014 , 88, 1189-203	38
261	The EGFR-mTOR pathway and laryngeal cancer angiogenesis. 2014 , 271, 757-64	18

260	Enhancement of gefitinib-induced growth inhibition by <i>Marsdenia tenacissima</i> extract in non-small cell lung cancer cells expressing wild or mutant EGFR. 2014 , 14, 165	19
259	Comparison of two site-specifically (18)F-labeled affibodies for PET imaging of EGFR positive tumors. 2014 , 11, 3947-56	49
258	Panitumumab (Vectibix [®]): A Treatment for Metastatic Colorectal Cancer. 2014 , 1855-1870	
257	Molecular Target Treatment for Personalized Radiotherapy in Lung Cancer. 2014 , 390-405	
256	Predictive biomarkers for anti-epidermal growth factor receptor therapy: beyond KRAS testing. 2014 , 12, 1433-42	5
255	Clinicopathological characteristics and prognostic impact of colorectal cancers with NRAS mutations. 2014 , 32, 50-6	29
254	Epirubicin inhibits growth and alters the malignant phenotype of the U-87 glioma cell line. 2015 , 12, 5917-23	6
253	Targeted Therapy in Solid Tumors: Colorectal Cancer. 2015 , 193-204	
252	On the Verge: Immunotherapy for Colorectal Carcinoma. 2015 , 13, 970-8	9
251	Panitumumab after progression on cetuximab in KRAS wild-type metastatic colorectal cancer patients: a single institution experience. 2015 , 101, 524-8	4
250	Positional isomerization of a non-cleavable combi-molecule dramatically altered tumor cell response profile. 2015 , 85, 153-62	3
249	LC-MS Method for the Quantitation of Two Monoclonal Antibodies by Multiple Signature Peptides in Monkey Serum. 2015 , 6,	
248	Amphiregulin enhances intercellular adhesion molecule-1 expression and promotes tumor metastasis in human osteosarcoma. 2015 , 6, 40880-95	20
247	Clinical Challenges to Current Molecularly Targeted Therapies in Lung Cancer. 2015 , 3,	1
246	Smart Mesoporous Nanomaterials for Antitumor Therapy. 2015 , 5, 1906-1937	65
245	Methamphetamine mediates immune dysregulation in a murine model of chronic viral infection. 2015 , 6, 793	14
244	Inhibition of hexokinase-2 with targeted liposomal 3-bromopyruvate in an ovarian tumor spheroid model of aerobic glycolysis. 2015 , 10, 4405-23	21
243	. 2015 ,	2

242	Fiber-Optic SPR Immunosensors Tailored To Target Epithelial Cells through Membrane Receptors. 2015 , 87, 5957-65	47
241	Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody. 2015 , 14, 1141-51	55
240	EGFR signaling in colorectal cancer: a clinical perspective. 2015 , 21	4
239	Targeted therapy in gastroesophageal cancers: past, present and future. 2015 , 3, 316-29	19
238	Eprobe-mediated screening system for somatic mutations in the KRAS locus. 2015 , 33, 2719-27	8
237	Hematologic toxicity assessment in solid tumor patients treated with cetuximab: a pooled analysis of 18 randomized controlled trials. 2015 , 136, 936-44	7
236	Tumor-associated hyaluronan limits efficacy of monoclonal antibody therapy. 2015 , 14, 523-32	89
235	A kinase-independent role for EGF receptor in autophagy initiation. 2015 , 160, 145-60	155
234	Nanocell targeting using engineered bispecific antibodies. 2015 , 7, 53-65	28
233	LAPTM4B is a PtdIns(4,5)P2 effector that regulates EGFR signaling, lysosomal sorting, and degradation. 2015 , 34, 475-90	57
232	In-depth N-glycome profiling of paired colorectal cancer and non-tumorigenic tissues reveals cancer-, stage- and EGFR-specific protein N-glycosylation. 2015 , 25, 1064-78	53
231	Nitric Oxide and Cancer: Pathogenesis and Therapy. 2015 ,	2
230	Hypersensitivity to biological agents—updated diagnosis, management, and treatment. 2015 , 3, 175-85; quiz 186	70
229	Glioblastoma multiforme: Pathogenesis and treatment. 2015 , 152, 63-82	370
228	PET Imaging in Head and Neck Cancer Patients to Monitor Treatment Response: A Future Role for EGFR-Targeted Imaging. 2015 , 21, 3602-9	22
227	The challenge of targeting metastasis. 2015 , 34, 635-41	98
226	Ultrasmall dual-modality silica nanoparticle drug conjugates: Design, synthesis, and characterization. 2015 , 23, 7119-30	22
225	Design of liposomal formulations for cell targeting. 2015 , 136, 514-26	91

224	Trastuzumab is not a tyrosine kinase inhibitor. 2015 , 12, 669	3
223	S-Nitrosylation in Cancer Cells: To Prevent or to Cause?. 2015 , 97-109	
222	Quercetin 3-O-glucoside suppresses epidermal growth factor-induced migration by inhibiting EGFR signaling in pancreatic cancer cells. 2015 , 36, 9385-93	38
221	First in human nanotechnology doxorubicin delivery system to target epidermal growth factor receptors in recurrent glioblastoma. 2015 , 22, 1889-94	62
220	mAb806 binding to epidermal growth factor receptor: a computational study. 2015 , 83, 153-68	3
219	Identification of ABC Transporter Interaction of a Novel Cyanoquinoline Radiotracer and Implications for Tumour Imaging by Positron Emission Tomography. 2016 , 11, e0161427	2
218	Role of targeted therapy in metastatic colorectal cancer. 2016 , 8, 642-55	67
217	Oncogenic fingerprint of epidermal growth factor receptor pathway and emerging epidermal growth factor receptor blockade resistance in colorectal cancer. 2016 , 7, 340-351	3
216	[Target Therapy in Unresectable or Metastatic Colorectal Cancer]. 2016 , 68, 303-311	5
215	Metabolic Imaging to Assess Treatment Response to Cytotoxic and Cytostatic Agents. 2016 , 6, 152	18
214	Rapid Diminution in the Level and Activity of DNA-Dependent Protein Kinase in Cancer Cells by a Reactive Nitro-Benzoxadiazole Compound. 2016 , 17,	10
213	Endothelial growth factor receptor inhibitors in recurrent metastatic cancer of the head and neck. 2016 , 38 Suppl 1, E2221-8	2
212	The Discovery of Dacomitinib, a Potent Irreversible EGFR Inhibitor. 2016 , 207-233	3
211	Molecular Targets in Advanced Therapeutics of Cancers: The Role of Pharmacogenetics. 2016 , 91, 3-12	8
210	PET imaging of epidermal growth factor receptor expression in tumours using ⁸⁹ Zr-labelled ZEGFR:2377 affibody molecules. 2016 , 48, 1325-32	41
209	Secretome Signature Identifies ADAM17 as Novel Target for Radiosensitization of Non-Small Cell Lung Cancer. 2016 , 22, 4428-39	28
208	Enhancing chemosensitivity in oral squamous cell carcinoma by lentivirus vector-mediated RNA interference targeting and. 2016 , 12, 2107-2114	3
207	Impact of the putative cancer stem cell markers and growth factor receptor expression on the sensitivity of ovarian cancer cells to treatment with various forms of small molecule tyrosine kinase inhibitors and cytotoxic drugs. 2016 , 49, 1825-1838	20

206	The strange connection between epidermal growth factor receptor tyrosine kinase inhibitors and dapson: from rash mitigation to the increase in anti-tumor activity. 2016 , 32, 1839-1848	15
205	Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4-d]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family. 2016 , 59, 8103-24	40
204	Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review 18. 2016 , 173, 1407-24	42
203	PET of EGFR with (64) Cu-cetuximab-F(ab') ₂ in mice with head and neck squamous cell carcinoma xenografts. 2016 , 11, 65-70	21
202	Actinidia chinensis Planch root extract (acRoots) inhibits hepatocellular carcinoma progression by inhibiting EP3 expression. 2016 , 32, 499-511	26
201	Type I [Phosphatidylinositol Phosphate 5-Kinase i5 Controls the Ubiquitination and Degradation of the Tumor Suppressor Mitogen-inducible Gene 6. 2016 , 291, 21461-21473	4
200	Nrf2 but not autophagy inhibition is associated with the survival of wild-type epidermal growth factor receptor non-small cell lung cancer cells. 2016 , 310, 140-149	9
199	A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer. 2016 , 115, 1206-1214	34
198	Combination therapy approaches to target insulin-like growth factor receptor signaling in breast cancer. 2016 , 23, R513-R536	12
197	HSP90 expression and its association with wighteone metabolite response in HER2-positive breast cancer cells. 2016 , 11, 3719-3722	12
196	Phase 1 Study of Monotherapy with KHK2866, an Anti-Heparin-Binding Epidermal Growth Factor-Like Growth Factor Monoclonal Antibody, in Patients with Advanced Cancer. 2016 , 11, 317-27	8
195	Epidermal Growth Factor Receptor Inhibition in the Management of Squamous Cell Carcinoma of the Lung. 2016 , 21, 205-13	21
194	ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope. 2016 , 15, 661-9	110
193	Stress-Induced EGFR Trafficking: Mechanisms, Functions, and Therapeutic Implications. 2016 , 26, 352-366	95
192	Maintenance Therapy in Colorectal Cancer: Moving the Artillery Down While Keeping an Eye on the Enemy. 2016 , 15, 7-15	3
191	Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics. 2016 , 22, 461-76	21
190	Neoplasms of the Head and Neck. 2017 , 1-37	
189	Increased Infiltration of Natural Killer and T Cells in Colorectal Liver Metastases Improves Patient Overall Survival. 2017 , 21, 1226-1236	44

188	Exocrine Gland Morphogenesis: Insights into the Role of Amphiregulin from Development to Disease. 2017 , 65, 477-499	5
187	An overall review of targeted therapy in solid cancers. 2017 , 7, 99-105	8
186	Colorectal cancer molecular profiling: from IHC to NGS in search of optimal algorithm. 2017 , 471, 235-242	6
185	Special types of folliculitis which should be differentiated from acne. 2017 , 9, e1356519	6
184	Mechanisms of human cytomegalovirus infection with a focus on epidermal growth factor receptor interactions. 2017 , 27, e1955	3
183	ZNF516 suppresses EGFR by targeting the CtBP/LSD1/CoREST complex to chromatin. 2017 , 8, 691	28
182	RANK and EGFR in invasive breast carcinoma. 2017 , 216-217, 61-66	10
181	Antibody-Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments. 2017 , 12, 719-739	51
180	Potential mechanisms of CD133 in cancer stem cells. 2017 , 184, 25-29	62
179	Pancreatic stellate cells in pancreatic cancer: In focus. 2017 , 17, 514-522	20
178	Clinical studies in humans targeting the various components of the IGF system show lack of efficacy in the treatment of cancer. 2017 , 772, 105-122	17
177	Theories of Aging and Chronic Diseases: Chronic Inflammation an Interdependent Roadmap to Age-Associated Illnesses. 2017 , 91-174	1
176	Metal Nanoparticles in Nanomedicine: Advantages and Scope. 2017 , 121-168	3
175	Design, Synthesis and Preliminary Biological Evaluation of Novel Benzyl Sulfoxide 2-Indolinone Derivatives as Anticancer Agents. 2017 , 22,	11
174	Highly Specific and Effective Targeting of EGFRvIII-Positive Tumors with TandAb Antibodies. 2017 , 7, 100	13
173	Chemotherapy Plus Cetuximab versus Chemotherapy Alone for Patients with KRAS Wild Type Unresectable Liver-Confined Metastases Colorectal Cancer: An Updated Meta-Analysis of RCTs. 2017 , 2017, 8464905	10
172	Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate. 2018 , 17, 795-805	26
171	Tumor Inhibition Achieved by Targeting and Regulating Multiple Key Elements in EGFR Signaling Pathway Using a Self-Assembled Nanoprodrug. 2018 , 28, 1800692	34

170	Targeting EGFR-mediated autophagy as a potential strategy for cancer therapy. 2018 , 143, 2116-2125	46
169	Impact of host cell line choice on glycan profile. 2018 , 38, 851-867	106
168	Galectin-8 induces partial epithelial-mesenchymal transition with invasive tumorigenic capabilities involving a FAK/EGFR/proteasome pathway in Madin-Darby canine kidney cells. 2018 , 29, 557-574	20
167	Influence of composition of cysteine-containing peptide-based chelators on biodistribution of Tc-labeled anti-EGFR affibody molecules. 2018 , 50, 981-994	11
166	Therapeutic targeting of PP2A. 2018 , 96, 182-193	82
165	EGFR Targeting and Shielding of pDNA Lipopolyplexes via Bivalent Attachment of a Sequence-Defined PEG Agent. 2018 , 18, 1700203	14
164	Frontline Systemic Therapy Options in Nonsmall Cell Lung Cancer. 2018 , 418-433.e6	
163	Cutaneous Reactions to Drugs. 2018 , 53-72	3
162	Prognostic and predictive value of EGFR and EGFR-ligands in blood of breast cancer patients: a systematic review. 2018 , 56, 688-701	21
161	Vaccine and immune cell therapy in non-small cell lung cancer. 2018 , 10, S1602-S1614	21
160	Biodistribution and Tumor Uptake of Ga-Nimotuzumab in a Malignant Pleural Mesothelioma Xenograft. 2018 , 23,	3
159	Synergistic inhibitory effects of cetuximab and curcumin on human cisplatin-resistant oral cancer CAR cells through intrinsic apoptotic process. 2018 , 16, 6323-6330	11
158	Oncogenic Signaling Induced by HCV Infection. 2018 , 10,	10
157	Significance of the epidermal growth factor receptor mutation status and differences among molecular subgroups in surgically resected lung microinvasive adenocarcinoma. 2018 , 16, 7057-7067	2
156	RANK-c attenuates aggressive properties of ER-negative breast cancer by inhibiting NF- κ B activation and EGFR signaling. 2018 , 37, 5101-5114	14
155	Cisplatin-induced non-canonical endocytosis of EGFR via p38 phosphorylation of the C-terminal region containing Ser-1015 in non-small cell lung cancer cells. 2018 , 15, 9251-9256	7
154	Growth Factors in the Intestinal Tract. 2018 , 71-101	3
153	Eicosanoids and HB-EGF/EGFR in cancer. 2018 , 37, 385-395	10

152	EGFR-mediated signaling pathway influences the sensitivity of oral squamous cell carcinoma to JQ1. 2018 , 119, 8368-8377	17
151	Predictive and Prognostic Implications of Mutation Profiling and Microsatellite Instability Status in Patients with Metastatic Colorectal Carcinoma. 2018 , 2018, 4585802	10
150	Exploring pitfalls of Cu-labeled EGFR-targeting peptide GE11 as a potential PET tracer. 2018 , 50, 1415-1431	10
149	Tumor-penetrating peptide fused EGFR single-domain antibody enhances radiation responses following EGFR inhibition in gastric cancer. 2018 , 40, 1583-1591	4
148	Prognostic significance of the expression of HER family members in primary osteosarcoma. 2018 , 16, 2185-2194	9
147	The Shifting Paradigm of Prognostic Factors of Colorectal Liver Metastases: From Tumor-Centered to Host Immune-Centered Factors. 2018 , 8, 181	11
146	Skin toxicity with anti-EGFR monoclonal antibody in cancer patients: a meta-analysis of 65 randomized controlled trials. 2018 , 82, 571-583	8
145	Current Molecular-Targeted Therapies in NSCLC and Their Mechanism of Resistance. 2018 , 10,	64
144	Upregulation of c-mesenchymal epithelial transition expression and mutations are associated with late lung metastasis and poor prognosis in colorectal carcinoma. 2018 , 15, 4229-4242	1
143	Mucositis with anti-EGFR monoclonal antibody in cancer patients: a meta-analysis of randomized controlled trials. 2018 , 48, 718-727	1
142	MicroRNAs in cancer drug resistance: Basic evidence and clinical applications. 2019 , 234, 2152-2168	42
141	Immunotherapies and Targeted Therapies in the Treatment of Metastatic Colorectal Cancer. 2019 , 7,	19
140	Metal-based antibody drug conjugates. Potential and challenges in their application as targeted therapies in cancer. 2019 , 199, 110780	19
139	Current Recommendations and Novel Strategies for the Management of Skin Toxicities Related to Anti-EGFR Therapies in Patients with Metastatic Colorectal Cancer. 2019 , 39, 825-834	9
138	Protein phosphatase 2A (PP2A): a key phosphatase in the progression of chronic obstructive pulmonary disease (COPD) to lung cancer. 2019 , 20, 222	9
137	Targeting EGFR pathway in metastatic colorectal cancer- tumour heterogeneity and convergent evolution. 2019 , 143, 153-163	31
136	Ex vivo tissue slice culture system to measure drug-response rates of hepatic metastatic colorectal cancer. 2019 , 19, 1030	14
135	Clinicopathological and prognostic values of ErbB receptor family amplification in primary osteosarcoma. 2019 , 79, 601-612	4

134	Low UBE4B expression increases sensitivity of chemoresistant neuroblastoma cells to EGFR and STAT5 inhibition. 2019 , 20, 1416-1429	3
133	Preparation of Lu-labeled Nimotuzumab for radioimmunotherapy of EGFR-positive cancers: Comparison of DOTA and CHX-A?-DTPA as bifunctional chelators. 2019 , 62, 158-165	3
132	2-(2-(2,4-dioxopentan-3-ylidene)hydrazineyl)benzotrile as novel inhibitor of receptor tyrosine kinase and PI3K/AKT/mTOR signaling pathway in glioblastoma. 2019 , 166, 291-303	29
131	Potential use of transrenal DNA for non-invasive monitoring and prognosis of colorectal cancer. 2019 , 24, 524-529	2
130	Cell-penetrable nanobodies (transbodies) that inhibit the tyrosine kinase activity of EGFR leading to the impediment of human lung adenocarcinoma cell motility and survival. 2019 , 120, 18077-18087	19
129	Monomethyl auristatin E-conjugated anti-EGFR antibody inhibits the growth of human EGFR-positive non-small cell lung cancer. 2019 , 84, 61-72	5
128	Dermatologic Toxicities: A Chart Review of Clinical Management Among Patients With Metastatic Colorectal Cancer Treated With Panitumumab. 2019 , 23, 157-164	1
127	To be or not to be: PP2A as a dual player in CNS functions, its role in neurodegeneration, and its interaction with brain insulin signaling. 2019 , 76, 2277-2297	8
126	Smart Targeting To Improve Cancer Therapeutics. 2019 , 13, 3753-3772	54
125	Lung carcinoma therapy using epidermal growth factor receptor-targeted lipid polymeric nanoparticles co-loaded with cisplatin and doxorubicin. 2019 , 42, 2087-2096	19
124	AIE-based cancer theranostics. 2020 , 402, 213076	80
123	Assessment of two different HER2 scoring systems and clinical relevance for colorectal cancer. 2020 , 476, 391-398	9
122	EGFR signaling augments TLR4 cell surface expression and function in macrophages via regulation of Rab5a activation. 2020 , 11, 144-149	7
121	FTIR spectra signatures reveal different cellular effects of EGFR inhibitors on nonsmall cell lung cancer cells. 2020 , 13, e201960012	6
120	A glance over doxorubicin based-nanotherapeutics: From proof-of-concept studies to solutions in the market. 2020 , 317, 347-374	33
119	Dissecting the molecular recognition of dual lapatinib derivatives for EGFR/HER2. 2020 , 34, 293-303	4
118	Promising Chimeric Antigen Receptors for Non-B-Cell Hematological Malignancies, Pediatric Solid Tumors, and Carcinomas. 2020 , 137-163	1
117	Utilization of Polymer-Lipid Hybrid Nanoparticles for Targeted Anti-Cancer Therapy. 2020 , 25,	22

116	Improving the Efficacy of Tumor Radiosensitization Through Combined Molecular Targeting. 2020 , 10, 1260	6
115	The lncRNA mediates renal cell cancer progression by regulating transcription and EGFR sialylation. 2020 , 133,	3
114	Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma by Targeting the Epidermal Growth Factor Receptor Combined with Gemcitabine Plus Platinum. 2020 , 12, 10353-10360	1
113	Exploring the radiosensitizing potential of AZD8931: a pilot study on the human LoVo colorectal cancer cell line. 2020 , 96, 1504-1512	
112	The study of EGFR-ligand complex electron property relationship with biological activity. 2020 , 1-14	
111	An Inside Job: Applications of Intracellular Single Domain Antibodies. 2020 , 10,	9
110	Nimotuzumab for Patients With Inoperable Cancer of the Head and Neck. 2020 , 10, 817	8
109	Regulation of Cancer Immune Checkpoints. 2020 ,	2
108	Spectrum of EGFR aberrations and potential clinical implications: insights from integrative pan-cancer analysis. 2020 , 40, 43-59	22
107	Anti-epidermal growth factor receptor monoclonal antibody plus palliative chemotherapy as a first-line treatment for recurrent or metastatic nasopharyngeal carcinoma. 2020 , 9, 1721-1732	5
106	Topical aloe vera for the treatment of cetuximab-related acneiform rash in colorectal cancer: A case report. 2021 , 27, 480-484	3
105	Mechanistic Analysis of an Extracellular Signal-Regulated Kinase 2-Interacting Compound that Inhibits Mutant BRAF-Expressing Melanoma Cells by Inducing Oxidative Stress. 2021 , 376, 84-97	1
104	Protein kinases as targets for developing anticancer agents from marine organisms. 2021 , 1865, 129759	0
103	Modulation of Signaling Pathways by Immunotherapeutics in Lung Cancer. 2021 , 241-261	
102	Advances in pathogenesis and precision medicine for nasopharyngeal carcinoma. 2021 , 2, 175-206	4
101	Design and Discovery of Kinase Inhibitors Using Docking Studies. 2021 , 337-365	
100	Focus on Multi-targeted Role of Curcumin: a Boon in Therapeutic Paradigm. 2021 , 28, 18893-18907	5
99	Human blood serum can donor-specifically antagonize effects of EGFR-targeted drugs on squamous carcinoma cell growth. 2021 , 7, e06394	5

98	VIRTUAL SCREENING AND IDENTIFICATION OF PLAUSIBLE NOVEL THERAPEUTIC EGFR INHIBITORS AGAINST BREAST CANCER. 2021 , 9, 481-491	
97	Erlotinib Promotes Ligand-Induced EGFR Degradation in 3D but Not 2D Cultures of Pancreatic Ductal Adenocarcinoma Cells. 2021 , 13,	2
96	Randomized phase III study of docetaxel versus docetaxel plus intercalated erlotinib in patients with relapsed non-squamous non-small cell lung carcinoma. 2021 , 160, 44-49	1
95	The Effects of Association of Topical Polydatin Improves the Preemptive Systemic Treatment on EGFR Inhibitors Cutaneous Adverse Reactions. 2021 , 10,	3
94	Activated epidermal growth factor receptor in ovarian cancer. 2009 , 149, 203-26	29
93	EGFR-Family Expression and Implications for Targeted Radionuclide Therapy. 2008 , 25-58	9
92	Aldo-Keto Reductases as New Therapeutic Targets for Colon Cancer Chemoresistance. 2013 , 109-133	6
91	Genetic Markers in Sporadic Tumors. 2008 , 43-84	2
90	Use of inhibitors in the study of MAP kinases. 2010 , 661, 107-22	19
89	Biology and Treatment of Basal-Like Breast Cancer. 2013 , 91-109	2
88	Checkpoints Under Traffic Control: From and to Organelles. 2020 , 1248, 431-453	3
87	Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family. 2008 , 118, 3574-81	84
86	Activation of Eatenin by oncogenic PIK3CA and EGFR promotes resistance to glucose deprivation by inducing a strong antioxidant response. 2012 , 7, e37526	7
85	Kaempferol Inhibits Pancreatic Cancer Cell Growth and Migration through the Blockade of EGFR-Related Pathway In Vitro. 2016 , 11, e0155264	68
84	Epidermal growth factor receptor inhibitors trigger a type I interferon response in human skin. 2016 , 7, 47777-47793	25
83	Extracellular domain shedding influences specific tumor uptake and organ distribution of the EGFR PET tracer ⁸⁹ Zr-imgatuzumab. 2016 , 7, 68111-68121	13
82	Novel multi-targeted ErbB family inhibitor afatinib blocks EGF-induced signaling and induces apoptosis in neuroblastoma. 2017 , 8, 1555-1568	17
81	Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancer. 2015 , 6, 5678-94	25

80	Identification of epidermal growth factor receptor and its inhibitory microRNA141 as novel targets of Krüppel-like factor 8 in breast cancer. 2015 , 6, 21428-42	18
79	A Retrospective Look at Anti-EGFR Agents in Pancreatic Cancer Therapy. 2019 , 20, 958-966	6
78	Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors. 2020 , 20, 815-834	64
77	Targeting Degradation of EGFR through the Allosteric Site Leads to Cancer Cell Detachment-Promoted Death. 2019 , 11,	8
76	Rash rates with egfr inhibitors: meta-analysis. 2011 , 18, e54-63	15
75	Bcl-x(L) and Myeloid cell leukaemia-1 contribute to apoptosis resistance of colorectal cancer cells. 2008 , 14, 3829-40	31
74	Clinical Profile of Cutaneous Adverse Effects of Epidermal Growth Factor Receptor Inhibitors: A Prospective Observational Study of 76 Cases. 2019 , 10, 251-255	8
73	Combined Inhibition of Epidermal Growth Factor Receptor and Cyclooxygenase-2 as a Novel Approach to Enhance Radiotherapy. 2011 , 1,	8
72	Efficacy and safety of panitumumab in a cohort of patients with metastatic colorectal cancer in France: PANI OUEST, a post-EMA-approval descriptive study with a geriatric oncology focus. 2020 , 31, 695-705	1
71	Association of human epidermal growth factor receptor-2 expression and clinicopathological findings in patients with colorectal cancer. 2012 , 13, 6221-5	6
70	Triple negative breast cancer. 2014 , 15, 2427-31	28
69	Receptor tyrosine kinases as a therapeutic target by natural compounds in cancer treatment. 2021 , 7,	1
68	Bispecific antibodies in colorectal cancer therapy: recent insights and emerging concepts. 2021 , 13, 1355-1367	0
67	Structure-function of EGFR kinase domain and its inhibitors. 2008 , 30-44	0
66	EGFR family heterodimers in cancer pathogenesis and treatment. 2008 , 14-29	3
65	Pharmacogenomics in Drug Development: A Pharmaceutical Industry Perspective. 2008 , 313-325	
64	Phase 1 Trials Today. 2008 , 553-570	
63	Sensitization of Epithelial Cancer Cells with Human Monoclonal Antibodies. 2008 , 3-11	

62 Molecular Assessment of Human Disease in the Clinical Laboratory. **2009**, 605-612

61 Targeting colorectal cancer with anti-epidermal growth factor receptor antibodies: focus on panitumumab. **2009**, 2, 161-70 2

60 Pharmacogenetics in Lung Cancer. **2010**, 87-99

59 Molecular Assessment of Human Disease in the Clinical Laboratory. **2010**, 413-420

58 Malignant disease of the breast. **2011**, 707-749

57 Encyclopedia of Cancer. **2011**, 1308-1310

56 Immunology of Head and Neck Cancer. **2011**, 107-119 1

55 Glioblastoma Cancer Stem Cells: Response to Epidermal Growth Factor Receptor Kinase Inhibitors. **2011**, 213-226

54 Targeted Therapies for Non-small-Cell Lung Cancer. **2012**, 93-114

53 Biological Treatments (Antibodies). **2013**, 915-948

52 Resistance to Anticancer Antibodies: From Mechanisms to Solutions. **2013**, 1-24

51 Induction of Selective Cell Death of Oral Squamous Carcinoma Cells by Integrin α Antibody and EGFR Antibody. **2013**, 35, 143-154

50 Epidermal Growth Factor Receptor Inhibitor Reactions. 184-195

49 Unraveling the role of epidermal growth factor receptor in oral lesions: Key to non surgical treatment modes. **2015**, 4, 22

48 Targeted Therapies For Intestinal Tumorigenesis. **2015**, 391-440

47 Encyclopedia of Cancer. **2015**, 1-3

46 Phase I Trials Today. **2015**, 661-676.e2

45 Encyclopedia of Cancer. **2015**, 1609-1612

44	Colorectal liver metastases. 2015 , 121-132	
43	Biological Principles and Clinical Application of EGFR Inhibitors in Cancer. 2017 , 709-726	
42	EGFR and Cytoplasmic Kinase Src Targeting in Pancreatic Cancer. 2018 , 97-105	
41	COX-2/C-MET/KRAS status-based prognostic nomogram for colorectal cancer: A multicenter cohort study. 2019 , 25, 293-301	1
40	Infusion Reaction to Monoclonal Antibodies in Outpatient Infusion Units of a University Hospital □ A Two-year Retrospective Study. 2019 , 3, 282-289	
39	Non-Small Cell Lung Carcinoma: EGFR Gene Mutations and Response to Gefitinib. 2008 , 291-306	
38	Lymphatic System in the Pathology of Cancer. 2008 , 225-241	
37	Introduction: the rationale for the development of targeted drugs in cancer therapy. 2007 , 172, 1-3	
36	Magnetic resonance imaging of the response of a mouse model of non-small cell lung cancer to tyrosine kinase inhibitor treatment. 2008 , 58, 276-81	7
35	Efficacy and safety evaluation of icotinib in patients with advanced non-small cell lung cancer. 2013 , 25, 90-4	12
34	Development and characterization of 89Zr-labeled panitumumab for immuno-positron emission tomographic imaging of the epidermal growth factor receptor. 2013 , 12, 17-27	38
33	Advances on EGFR mutation for lung cancer. 2012 , 1, 5-13	38
32	Cutaneous adverse reactions specific to epidermal growth factor receptor inhibitors. 2015 , 8 Spec Issue, 57-61	6
31	Second-line panitumumab as a triweekly dose for patients with wild-type KRAS exon 2 metastatic colorectal cancer: a single-institution experience. 2016 , 13, 136-41	1
30	Association of Cardiotoxicity With Doxorubicin and Trastuzumab: A Double-Edged Sword in Chemotherapy. 2021 , 13, e18194	3
29	Colorectal Cancer Progression Is Potently Reduced by a Glucose-Free, High-Protein Diet: Comparison to Anti-EGFR Therapy. 2021 , 13,	0
28	Nimotuzumab for COVID-19: case series. 2021 ,	0
27	Glycosylation promotes the cancer regulator EGFR-ErbB2 heterodimer formation - molecular dynamics study. 2021 , 27, 361	1

- 26 Quantitative parameters of magnetic resonance imaging cannot predict human epidermal growth factor receptor 2 (HER2) status in rectal cancer.. **2021**, 83, 77-82
- 25 Intramammary edema of invasive breast cancers on MRI T-weighted fat suppression sequence: Correlation with molecular subtypes and clinical-pathologic prognostic factors.. **2022**, 83, 87-92
- 24 Role and mechanism of action of LPTM4B in EGFR-mediated autophagy.. **2022**, 23, 109 0
- 23 Genetic Therapy and Molecular Targeted Therapy in Oncology: Safety, Pharmacovigilance, and Perspectives for Research and Clinical Practice.. **2022**, 23, 0
- 22 Blocking EGFR with nimotuzumab: a novel strategy for COVID-19 treatment.. **2022**, 0
- 21 O-GlcNAcylation regulates epidermal growth factor receptor intracellular trafficking and signaling.. **2022**, 119, e2107453119 1
- 20 Optimal solutions in the third line therapy for refractory metastatic colorectal cancer. CORRECTness and CONCUREncy. **2021**, 47-52
- 19 The ADAM17-directed Inhibitory Antibody MEDI3622 Antagonizes Radiotherapy-induced VEGF Release and Sensitizes NonSmall Cell Lung Cancer for Radiotherapy. **2021**, 1, 164-177 1
- 18 NK Cells Armed with Chimeric Antigen Receptors (CAR): Roadblocks to Successful Development.. **2021**, 10, 4
- 17 Image_1.pdf. **2020**,
- 16 Design, synthesis, and molecular docking studies of novel pomalidomide-based PROTACs as potential anti-cancer agents targeting EGFR and EGFR.. **2022**, 37, 1196-1211 5
- 15 Targeting mitochondrial metabolism for metastatic cancer therapy. 0
- 14 Adverse events secondary to cetuximab therapy in head & neck cancer therapy and risk factors for serious outcomes. **2022**, 131, 105952
- 13 Safety and tolerability of intravitreal cetuximab in young and adult rabbits. **2022**, 12,
- 12 Nimotuzumab Increases the Recovery Rate of Severe and Critical COVID-19 Patients: Evaluation in the Real-World Scenario. 10,
- 11 HER2 overexpression/amplification status in colorectal cancer: a comparison between immunohistochemistry and fluorescence in situ hybridization using five different immunohistochemical scoring criteria.
- 10 Human Blood Serum Inhibits Ductal Carcinoma Cells BT474 Growth and Modulates Effect of HER2 Inhibition. **2022**, 10, 1914
- 9 The Potential Clinical Uses and Nanoformulation Strategies of Kaempferol, a Dietary Flavonoid. **2022**, 32, 693-707 0

- 8 Development of Targeted EGFR Degradation for Cancer Treatment. **2022**, 122, 218-227
- 7 Nimotuzumab combined with chemoradiotherapy for the treatment of cervical cancer: A meta-analysis of randomized controlled trials. 12,
- 6 Neoplasms of the Head and Neck. 1-28
- 5 An ultra-performance LCMS/MS method for determination of JRF103 in human plasma: application in first-in-patient study.
- 4 The lysosome as a novel therapeutic target of EGFR-mediated tumor inflammation. 13,
- 3 Integrated bioinformatics and in silico approaches reveal the biological targets and molecular mechanisms of 1,25-dihydroxyvitamin D against COVID-19 and diabetes mellitus. 9,
- 2 Traditional Chinese medicine for colorectal cancer treatment: potential targets and mechanisms of action. **2023**, 18,
- 1 A new paradigm for epidermal growth factor receptor expression exists in PTC and NIFTP regulated by microRNAs. 13,